<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134897</url>
  </required_header>
  <id_info>
    <org_study_id>RuCorT-02</org_study_id>
    <nct_id>NCT04134897</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer</brief_title>
  <acronym>RuCorT-02</acronym>
  <official_title>A Multicenter Prospective Phase III Clinical Trial of Neoadjuvant CapOx in Patients With Intermediate Risk CRM-negative Middle Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 3 months of neoadjuvant CapOx is&#xD;
      non-inferior to neoadjuvant radiotherapy in patients with moderate risk CRM&quot;-&quot; mid rectal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to investigate the efficacy of neoadjuvant chemotherapy compared to 5x5 Gy&#xD;
      neoadjuvant radiotherapy in moderate risk CRM-negative rectal cancer patients. This is a&#xD;
      prospective multicenter open-label non-inferiority randomized phase III clinical trial.&#xD;
      Patients will be randomized using an online randomization system to receive either 4 cycles&#xD;
      of neoadjuvant CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days&#xD;
      1-14) chemotherapy, surgery and 4 cycles of adjuvant CapOx chemotherapy or 5x5 Gy&#xD;
      radiotherapy, surgery and 8 cycles of adjuvant CapOx chemotherapy. A stratification will be&#xD;
      performed based on сN stage and clinical center. Patients with сT3c-T3dN0-1M0, cT1-T3dN2M0&#xD;
      cancer in the middle rectum are included. Chemoradiotherapy (50 Gy with concomitant&#xD;
      capecitabine 825 mg/m2 per os bid on radiation days) will be performed for patients with&#xD;
      tumor progression after neoadjuvant chemotherapy. The main hypothesis is that the 2-year&#xD;
      local recurrence rate is non-inferior after neoadjuvant chemotherapy and neoadjuvant&#xD;
      radiotherapy in moderate risk mid rectal cancer patients. The target accrual is 158 patients&#xD;
      in each treatment arm (including 10% potential data loss) based on non-recurrence rate of 98%&#xD;
      in investigated and 96% in the control group with a non-inferiority margin of 3%, α=0,05,&#xD;
      power 80%. An interim analysis is planned after 50% of the patients will reach a 2-year&#xD;
      followup. Pelvic Magnetic Resonance Imaging (MRI) is performed in all patients for staging&#xD;
      before and after neoadjuvant chemotherapy and before surgery. Pelvic MRI is subject to&#xD;
      central review. Conduction of this study and data collection are controlled by a local&#xD;
      institutional board.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year local recurrence rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjuvant chemotherapy compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who receive a complete course of adjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute chemotherapy toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Toxicity measured according to NCI-CTCAE v.5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response rate (pCR)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year disease-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>Morbidity measured according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neoadjuvant chemotherapy disease progression rate</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients with disease progression during neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative tumor-associated complications rate</measure>
    <time_frame>3 months</time_frame>
    <description>The rate of tumor-associated complications (bowel obastruction, bleeding etc) during neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Rectal Neoplasms Malignant</condition>
  <condition>Rectum Carcinoma</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery within 2 weeks. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 8-10 weeks. After surgery patients receive 4 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 5x5 Gy radiotherapy and then surgery following 6-8 weeks. After surgery patients receive 8 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000 mg/m2, bid, per os, days 1-14, 4 cycles</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant radiotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m2 iv day 1, 4 cycles</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal cancer surgery</intervention_name>
    <description>Laparoscopic or open total mesorectal excision</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions</description>
    <arm_group_label>Neoadjuvant radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Histologically verified colon rectal adenocarcinoma&#xD;
&#xD;
          -  сT3c-T3dN0-1M0, cT1-T3dN2M0. cancer of the middle rectum (based on pelvic MRI)&#xD;
&#xD;
          -  Tumor more than 2 mm from mesorectal fascia (based on pelvic MRI)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) status 0-2&#xD;
&#xD;
          -  Haemoglobin (HGB) &gt; 90 g/L&#xD;
&#xD;
          -  Platelet Count (PLT) &gt; 120x10*9/L&#xD;
&#xD;
          -  Serum creatinine &lt; 150 µmol/L&#xD;
&#xD;
          -  Total bilirubin &lt; 25 µmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to obtain informed consent&#xD;
&#xD;
          -  distant metastases&#xD;
&#xD;
          -  synchronous or metachronous tumors&#xD;
&#xD;
          -  previous chemotherapy or radiotherapy&#xD;
&#xD;
          -  clinically significant cardiovascular disorders (myocardial infarction &lt; 6 months&#xD;
             before visit, stroke &lt; &lt; 6 months before visit, instable angina &lt; 3 months before&#xD;
             visit, arrhythmia, uncontrolled hypertension &gt; 160/100 mm hg&#xD;
&#xD;
          -  clinically significant neurological disorders&#xD;
&#xD;
          -  previous neuropathy 2 or higher&#xD;
&#xD;
          -  current infection or heavy systemic disease&#xD;
&#xD;
          -  pregnancy, breastfeeding&#xD;
&#xD;
          -  ulcerative colitis&#xD;
&#xD;
          -  individual intolerance to treatment components&#xD;
&#xD;
          -  proven dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
          -  participation in other clinical trials&#xD;
&#xD;
          -  psychiatric disorders, which render patient unable to follow instructions or&#xD;
             understand his/her condition&#xD;
&#xD;
          -  technical inability to perform pelvic MRI&#xD;
&#xD;
          -  inability of long-term followup of the patient&#xD;
&#xD;
          -  HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaman Z Mamedli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N.Blokhin Russian Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>N.N.Blokhin Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 19, 2019</study_first_submitted>
  <study_first_submitted_qc>October 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>February 7, 2021</last_update_submitted>
  <last_update_submitted_qc>February 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Blokhin's Russian Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Sergey Gordeyev</investigator_full_name>
    <investigator_title>Principal Investigator, Consultant surgeon</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>neoadjuvant radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

